vs

Side-by-side financial comparison of John Marshall Bancorp, Inc. (JMSB) and STANDARD BIOTOOLS INC. (LAB). Click either name above to swap in a different company.

STANDARD BIOTOOLS INC. is the larger business by last-quarter revenue ($19.6M vs $16.8M, roughly 1.2× John Marshall Bancorp, Inc.). John Marshall Bancorp, Inc. runs the higher net margin — 36.3% vs -177.4%, a 213.7% gap on every dollar of revenue. Over the past eight quarters, John Marshall Bancorp, Inc.'s revenue compounded faster (15.3% CAGR vs -12.2%).

John Marshall Bancorp, Inc. is a U.S.-based bank holding company that operates through its wholly owned subsidiary John Marshall Bank. It provides a full suite of commercial and consumer banking products including deposit accounts, commercial loans, residential mortgages, and personal financial services, primarily serving retail customers and small-to-mid-sized businesses across the U.S. Mid-Atlantic region.

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

JMSB vs LAB — Head-to-Head

Bigger by revenue
LAB
LAB
1.2× larger
LAB
$19.6M
$16.8M
JMSB
Higher net margin
JMSB
JMSB
213.7% more per $
JMSB
36.3%
-177.4%
LAB
Faster 2-yr revenue CAGR
JMSB
JMSB
Annualised
JMSB
15.3%
-12.2%
LAB

Income Statement — Q1 FY2026 vs Q3 FY2025

Metric
JMSB
JMSB
LAB
LAB
Revenue
$16.8M
$19.6M
Net Profit
$6.1M
$-34.7M
Gross Margin
48.5%
Operating Margin
-168.5%
Net Margin
36.3%
-177.4%
Revenue YoY
-11.5%
Net Profit YoY
26.8%
-28.8%
EPS (diluted)
$0.43
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
JMSB
JMSB
LAB
LAB
Q1 26
$16.8M
Q4 25
$16.4M
Q3 25
$16.3M
$19.6M
Q2 25
$15.4M
$21.8M
Q1 25
$14.6M
$40.8M
Q4 24
$14.3M
Q3 24
$13.8M
$22.1M
Q2 24
$12.6M
$22.5M
Net Profit
JMSB
JMSB
LAB
LAB
Q1 26
$6.1M
Q4 25
$5.9M
Q3 25
$5.4M
$-34.7M
Q2 25
$5.1M
$-33.5M
Q1 25
$4.8M
$-26.0M
Q4 24
$4.8M
Q3 24
$4.2M
$-26.9M
Q2 24
$3.9M
$-45.7M
Gross Margin
JMSB
JMSB
LAB
LAB
Q1 26
Q4 25
Q3 25
48.5%
Q2 25
48.8%
Q1 25
48.4%
Q4 24
Q3 24
54.9%
Q2 24
46.1%
Operating Margin
JMSB
JMSB
LAB
LAB
Q1 26
Q4 25
47.4%
Q3 25
42.2%
-168.5%
Q2 25
42.7%
-118.1%
Q1 25
42.4%
-80.8%
Q4 24
42.5%
Q3 24
38.8%
-120.9%
Q2 24
39.7%
-134.5%
Net Margin
JMSB
JMSB
LAB
LAB
Q1 26
36.3%
Q4 25
36.2%
Q3 25
33.2%
-177.4%
Q2 25
33.1%
-153.7%
Q1 25
32.9%
-63.8%
Q4 24
33.3%
Q3 24
30.7%
-122.0%
Q2 24
30.9%
-203.3%
EPS (diluted)
JMSB
JMSB
LAB
LAB
Q1 26
$0.43
Q4 25
$0.41
Q3 25
$0.38
$-0.09
Q2 25
$0.36
$-0.09
Q1 25
$0.34
$-0.07
Q4 24
$0.33
Q3 24
$0.30
$-0.07
Q2 24
$0.27
$-0.12

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
JMSB
JMSB
LAB
LAB
Cash + ST InvestmentsLiquidity on hand
$150.2M
$129.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$268.1M
$399.7M
Total Assets
$2.4B
$539.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
JMSB
JMSB
LAB
LAB
Q1 26
$150.2M
Q4 25
$130.0M
Q3 25
$163.6M
$129.4M
Q2 25
$116.9M
$158.6M
Q1 25
$169.1M
$150.9M
Q4 24
$122.5M
Q3 24
$177.2M
$210.6M
Q2 24
$182.6M
$269.8M
Total Debt
JMSB
JMSB
LAB
LAB
Q1 26
Q4 25
$80.9M
Q3 25
$80.9M
Q2 25
$80.8M
Q1 25
$80.8M
Q4 24
$80.8M
Q3 24
$80.8M
$55.2M
Q2 24
$24.7M
$55.1M
Stockholders' Equity
JMSB
JMSB
LAB
LAB
Q1 26
$268.1M
Q4 25
$265.6M
Q3 25
$259.7M
$399.7M
Q2 25
$253.7M
$424.5M
Q1 25
$253.0M
$454.6M
Q4 24
$246.6M
Q3 24
$243.1M
$489.3M
Q2 24
$235.3M
$510.3M
Total Assets
JMSB
JMSB
LAB
LAB
Q1 26
$2.4B
Q4 25
$2.3B
Q3 25
$2.3B
$539.6M
Q2 25
$2.3B
$557.0M
Q1 25
$2.3B
$579.6M
Q4 24
$2.2B
Q3 24
$2.3B
$681.5M
Q2 24
$2.3B
$708.7M
Debt / Equity
JMSB
JMSB
LAB
LAB
Q1 26
Q4 25
0.30×
Q3 25
0.31×
Q2 25
0.32×
Q1 25
0.32×
Q4 24
0.33×
Q3 24
0.33×
0.11×
Q2 24
0.11×
0.11×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
JMSB
JMSB
LAB
LAB
Operating Cash FlowLast quarter
$-22.2M
Free Cash FlowOCF − Capex
$-23.1M
FCF MarginFCF / Revenue
-118.1%
Capex IntensityCapex / Revenue
4.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-111.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
JMSB
JMSB
LAB
LAB
Q1 26
Q4 25
$22.6M
Q3 25
$1.2M
$-22.2M
Q2 25
$7.5M
$-20.7M
Q1 25
$7.0M
$-30.3M
Q4 24
$17.3M
Q3 24
$1.4M
$-27.9M
Q2 24
$10.2M
$-39.0M
Free Cash Flow
JMSB
JMSB
LAB
LAB
Q1 26
Q4 25
$22.0M
Q3 25
$1.2M
$-23.1M
Q2 25
$7.4M
$-22.6M
Q1 25
$6.6M
$-35.3M
Q4 24
$16.8M
Q3 24
$1.3M
$-30.1M
Q2 24
$10.1M
$-41.0M
FCF Margin
JMSB
JMSB
LAB
LAB
Q1 26
Q4 25
134.7%
Q3 25
7.3%
-118.1%
Q2 25
47.8%
-103.6%
Q1 25
45.3%
-86.6%
Q4 24
116.9%
Q3 24
9.5%
-136.4%
Q2 24
80.1%
-182.2%
Capex Intensity
JMSB
JMSB
LAB
LAB
Q1 26
Q4 25
3.4%
Q3 25
0.2%
4.5%
Q2 25
1.0%
8.7%
Q1 25
2.3%
12.4%
Q4 24
3.4%
Q3 24
0.8%
10.2%
Q2 24
0.4%
8.6%
Cash Conversion
JMSB
JMSB
LAB
LAB
Q1 26
Q4 25
3.82×
Q3 25
0.23×
Q2 25
1.48×
Q1 25
1.45×
Q4 24
3.61×
Q3 24
0.33×
Q2 24
2.60×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

JMSB
JMSB

Net Interest Income$16.5M98%
Noninterest Income$284.0K2%

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

Related Comparisons